Please login to the form below

Not currently logged in
Email:
Password:

obinutuzumab

This page shows the latest obinutuzumab news and features for those working in and with pharma, biotech and healthcare.

Roche and AbbVie prepare to move Venclexta into first-line CLL

Roche and AbbVie prepare to move Venclexta into first-line CLL

Venclexta (venetoclax) given in combination with Roche’s anti-CD20 drug Gazyva/Gazyvaro (obinutuzumab) has been shown to extend progression-free survival (PFS) compared to Gazyva plus chlorambucil chemotherapy – already approved

Latest news

More from news
Approximately 11 fully matching, plus 18 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Random42 Scientific Communication

Random42 is the world's leading medical animation company. Over the past 25 years we have produced core digital assets for...

Latest intelligence

Unlocking the potential of science and technology in the UK
Greater collaboration is vital in post-Brexit UK, says Alderley Park leader...
NHS regional footprints
What to expect from 2019...
Not another weight-loss ad
Christmas is over and the gyms are packed, it’s a never-ending tale. But why do we do it to ourselves every year?...

Infographics